The Definitive Peptide Research Reference Guide — Compound Review

Home Compounds BPC-157 TB-500 CJC-1295 Ipamorelin GLP-1 GHK-Cu Epithalon NAD+ Comparisons BPC-157 vs TB-500 Sermorelin vs Ipamorelin Semaglutide vs Tirzepatide Guides GHK-Cu Guide GHRH Analogues Ipamorelin Guide Peptide Reconstitution Guide Peptide Injection Sites Guide Peptide Storage Guide Semaglutide Dosage BPC-157 Dosage Research Guides Joint Pain Weight Loss Longevity Vendor Scoreboard All Vendor Comparisons Peptide Price Comparison Vendor Closures & Status How to Read a Peptide COA How to Vet a Peptide Vendor Why Purgo Labs Purgo Labs Review Purgo Labs Discount Code Where to Buy by Compound Legal Status Shop Purgo Labs

Semaglutide vs Mounjaro

Semaglutide vs Mounjaro (tirzepatide): pure GLP-1 agonist vs dual GLP-1/GIP agonist. Semaglutide and Mounjaro are different molecules — Mounjaro contains tirzepatide, not semaglutide.

Different Molecules

Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are distinct molecules. Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GLP-1/GIP receptor agonist. They are related in mechanism but not the same compound.

Weight Loss Comparison

Semaglutide (STEP-1): 14.9% weight loss at 68 weeks. Tirzepatide/Mounjaro (SURMOUNT-1): 20.9% at 72 weeks. SURPASS-2 direct comparison: tirzepatide 15 mg showed significantly greater weight loss than semaglutide 1 mg.

GIP Receptor Contribution

The GIP receptor agonism in tirzepatide (Mounjaro) is the key mechanistic difference. GIP receptor activation improves insulin sensitivity in adipose tissue and may reduce the nausea associated with pure GLP-1 agonists like semaglutide.